Compare ADPT & DGII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | DGII |
|---|---|---|
| Founded | 2009 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2019 | 1995 |
| Metric | ADPT | DGII |
|---|---|---|
| Price | $14.08 | $56.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $17.78 | ★ $48.80 |
| AVG Volume (30 Days) | ★ 1.8M | 241.9K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.89 | ★ 77.05 |
| EPS | N/A | ★ 0.31 |
| Revenue | $276,976,000.00 | ★ $430,221,000.00 |
| Revenue This Year | $3.98 | $18.71 |
| Revenue Next Year | $22.72 | $7.22 |
| P/E Ratio | ★ N/A | $181.26 |
| Revenue Growth | ★ 54.77 | 1.46 |
| 52 Week Low | $7.16 | $26.69 |
| 52 Week High | $20.76 | $56.88 |
| Indicator | ADPT | DGII |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 69.29 |
| Support Level | $12.22 | $47.00 |
| Resistance Level | $17.52 | N/A |
| Average True Range (ATR) | 0.84 | 1.76 |
| MACD | 0.06 | 0.23 |
| Stochastic Oscillator | 54.11 | 91.70 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.